马拉维青少年及成人伯基特淋巴瘤治疗的前瞻性研究
该前瞻性研究纳入马拉维2013至2018年35例15岁及以上新诊断伯基特淋巴瘤患者,中位年龄21岁,43%合并HIV感染,77%为III-IV期。中位总生存期7个月,1年OS为40%(95%CI 24%-56%),28例可评估者中14例(50%)达完全缓解。与CHOP相比,更强方案似乎降低死亡风险(HR 0.24,95%CI 0.05-1.02,P=.05)。
要点
- 该前瞻队列中位OS仅7个月,1年OS为40%(95%CI 24%-56%)。
- 28例可评估患者中14例(50%)达完全缓解。
- 更强化疗方案与更低死亡风险相关(HR 0.24,95%CI 0.05-1.02,P=.05)。
核心结论
- 这是撒哈拉以南非洲地区 characterization 较好的非儿童伯基特淋巴瘤前瞻性队列之一,多数死亡由疾病进展导致,接受更强治疗的患者似乎结局更好。
研究设计与样本
- 前瞻性研究,2013至2018年在马拉维纳入35例15岁及以上新诊断伯基特淋巴瘤患者,化疗按机构指南实施,HIV感染者同时接受抗逆转录病毒治疗。
主要发现
- 中位年龄21岁(范围15-61),15例(43%)HIV感染,27例(77%)为III-IV期,19例(54%)ECOG体能状态>1。
- HIV感染者中位CD4计数130(范围29-605),10例(67%)HIV病毒载量抑制。
- 4例(11%)在化疗前死亡。
- 一线化疗方案:CHOP 22例(71%),输注依托泊苷+泼尼松龙+长春新碱+环磷酰胺+多柔比星4例(13%),大剂量甲氨蝶呤为基础方案4例(13%),利妥昔单抗+CHOP 1例(3%)。
- 28例可评估患者中14例(50%)达完全缓解;中位OS为7个月,1年OS为40%(95%CI 24%-56%);22例死亡中16例(73%)死于疾病进展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burkitt lymphoma (BL) is common in sub-Saharan Africa (SSA). In high-income countries, BL is highly curable with chemotherapy. However, there are few prospective studies from SSA describing nonpediatric BL and no regional standard of care. Thirty-five participants age 15 years or older with newly diagnosed BL were enrolled in Malawi from 2013 to 2018. Chemotherapy was administered according to institutional guidelines, with concurrent antiretroviral therapy if HIV infected. Median age was 21 years (range, 15-61) and 15 participants (43%) were HIV infected. Twenty-seven participants (77%) had stage III to IV disease, and 19 (54%) had Eastern Cooperative Oncology Group performance status >1. Among HIV-infected participants, median CD4 count was 130 (range, 29-605) and 10 (67%) had suppressed HIV viral load. Four participants (11%) died before receiving chemotherapy. First-line chemotherapy consisted of: cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (n = 22 [71%]); infusional etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin (n = 4 [13%]); high-dose methotrexate-based chemotherapy (n = 4 [13%]); and rituximab plus CHOP (n = 1 [3%]). Among 28 evaluable participants, 14 (50%) achieved a complete response. Median overall survival (OS) was 7 months; 1-year OS was 40% (95% confidence interval [CI], 24%-56%). Sixteen (73%) of 22 deaths were a result of disease progression. Compared with CHOP, more intensive chemotherapy was associated with decreased mortality (hazard ratio, 0.24; 95% CI, 0.05-1.02; P = .05). This is among the best characterized prospective cohorts of nonpediatric BL in SSA. Most deaths resulted from progressive BL. Patients who received more intensive therapy seemed to have better outcomes. Defining optimal approaches is an urgent priority in SSA.
引用
- Painschab MS, Westmoreland KD, Kasonkanji E, et al. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi. Blood Adv. 2019. PMID: 30796065. doi:10.1182/bloodadvances.2018029199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。